Severe hypocalcemia following denosumab injection in patient with chronic kidney disease

Nefrologia. 2016 Jul-Aug;36(4):446-8. doi: 10.1016/j.nefro.2016.02.007. Epub 2016 Mar 21.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adrenal Cortex Hormones / adverse effects
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Calcitriol / therapeutic use
  • Calcium Carbonate / therapeutic use
  • Chelating Agents / therapeutic use
  • Cholecalciferol / therapeutic use
  • Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy
  • Chronic Kidney Disease-Mineral and Bone Disorder / etiology
  • Denosumab / administration & dosage
  • Denosumab / adverse effects*
  • Glomerulosclerosis, Focal Segmental / complications
  • Glomerulosclerosis, Focal Segmental / therapy
  • Humans
  • Hypocalcemia / chemically induced*
  • Male
  • Nephrotic Syndrome / drug therapy
  • Nephrotic Syndrome / etiology
  • Osteoporosis / chemically induced
  • Osteoporosis / drug therapy
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / etiology
  • Sevelamer / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Chelating Agents
  • Cholecalciferol
  • Denosumab
  • Sevelamer
  • Calcitriol
  • Calcium Carbonate